Anavex Life Sciences Reports Positive Results in Parkinson’s Disease Dementia Study
Anavex Life Sciences has announced promising findings from the 48-week, open-label extension of its phase 2 study involving ANAVEX2-73, also known as blarcamesine, in patients […]